After the last pump and dump of IGC caused by Cohort 2 of IGC`s Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients
now India Globalization Capital comes with another bullish news on the subject: the cannabis-based investigational drug IGC-AD1 was safe and well-tolerated by the Alzheimer’s trial participants!
My first target is the 2.10usd resistance.
